Professional Documents
Culture Documents
1. See Also
1. Diabetes Mellitus Glucose Management
2. Type I Diabetes Mellitus
3. Type II Diabetes Mellitus
4. Insulin Resistance Syndrome
5. Diabetes Mellitus Education
2. Definition
1. Metabolic disorder of carbohydrate economy
2. Deficiency of pancreatic beta cell Insulin secretion
3. Resistance to Insulin effect peripherally
3. Epidemiology (U.S. statistics for 2004 per ADA)
1. Prevalence
1. Type I Diabetes Mellitus: 750,000
2. Type II Diabetes Mellitus: 13 million
3. Gestational Diabetes: 135,000
4. Undiagnosed with diabetes: 5.2 million
2. Incidence
1. Type 1: 30,000 new cases per year
2. Type 2: 850,000 new cases per year
3. Gestational Diabetes Mellitus: 4% of all pregnancies
4. Fastest growing groups
1. Ages 30 to 39 years
2. Type II Diabetes in children
4. Types
1. Type I Diabetes Mellitus
1. Juvenile Diabetes Mellitus
2. Insulin Dependent Diabetes Mellitus (IDDM)
2. Type II Diabetes Mellitus
1. Adult onset Diabetes Mellitus
2. Non-Insulin Dependent Diabetes Mellitus (NIDDM)
3. Pediatric Type II Diabetes Mellitus (Pediatric NIDDM)
4. Maturity onset Diabetes of youth (MODY)
5. Symptoms
1. Classic (75% of cases of Type I Diabetes Mellitus)
1. Polyuria or nocturia
2. Polydipsia
3. Unexplained Weight Loss
2. Other symptoms
1. Increased appetite
2. Blurred vision
3. Frequent Urinary Tract Infections
4. Frequent yeast infections
5. Fatigue
6. Dry or pruritic skin
7. Numbness or tingling in the extremities
6. Diagnostic Criteria
1. Random Serum Glucose
1. Serum Glucose over 200 mg/dl with symptoms
2. Fasting Serum Glucose
1. Serum Glucose exceeds 126 mg/dl on 2 different days
3. Postprandial Glucose (2 hours post meal)
1. Serum Glucose over 200 mg/dl
2. Precedes fasting glucose increase
3. More predictive of Diabetes Mellitus Complications
4. Casual Plasma Glucose (random glucose)
1. Same criteria as postprandial glucose
5. Oral Glucose Tolerance Test (OGGT)
1. Two hour Glucose Tolerance Test (75 gram) >200 mg/dl
2. Consider in patients with Insulin Resistance
1. Patients with pre-diabetes to qualify for education
7. Other monitoring
1. Home Serum Glucose monitoring
1. Over 50% of values should fall in target range
8. Management: Severe Hyperglycemia at diagnosis
1. Start Insulin at onset if severe hyperglycemia
2. Criteria
1. Blood Glucose >300 mg/dl
2. Hemoglobin A1C >9.0
3. Protocol based on Urine Ketones
1. Urine Ketones positive
1. Evaluate for Diabetic Ketoacidosis
2. Check Metabolic panel and Serum Ketones
2. Urine Ketones negative
1. Type I vs Type II is not critical initially
1. Both get Insulin at this hyperglycemia level
2. Type II suspected
1. Consider adding Metformin
2. Insulin can likely be weaned later
1. Glucose toxicity causes low Insulin
level
2. Endogenous Insulin will later
normalize
2. Start LantusInsulin at 10 units SQ today
1. Low risk of Hypoglycemia
3. Teach glucose testing, Insulin injection today
1. Formal Diabetic Education within 1 week
2. Consider endocrinology consultation later
4. Give prescriptions today
1. Meter, strips, lancets, Insulin, syringes
9. Management: Initial Education
1. Key Topics
1. See Diabetes Mellitus Glucose Management
2. See Diabetes Mellitus Education
2. Type specific Diabetes Information
1. See Type I Diabetes Mellitus
2. See Type II Diabetes Mellitus
3. Adjunctive Management
1. See Hypertension in Diabetes Mellitus
2. See Coronary Artery Disease Prevention in Diabetes
3. Tobacco Cessation
4. Weight loss
5. Aspirin in all diabetic patients
6. Consider ACE Inhibitor in all diabetic patients
1. Use low dose (2.5 to 5 mg) in normotensive patient
7. Lipid disorders
1. See Coronary Artery Disease Prevention in Diabetes
2. See Low Fat Diet
3. See AntiHyperlipidemic
Advertisement
Sports Medicine
Mario Cesar Moreira de Araujo, MD & Marcelo Riccio Facio, MD
Medstudents' Homepage
Introduction
Nowadays the development of convinient and efficient ways of self monitoring blood
glucose, ande the admission of benefits of regular exercing permit and enconrage more
diabetics to engage into exercise programs. Consequenty, phisicians will have to be able
to prescribe arrangements in calorie ingestion and insulin dosage, as well imagine
possible hypoglycemia and unexpected prolonged exercise to permit a safe participation
on this activities.
This chapter entends help the medical student to “get contact” with clinical control of
IDDM and NIDDM patients and is diveded in four basical parts: (1) Normal Metabolism
During Exercise (2) Utilization of glucose on diabetics that exercise themselves (3)
Beneficts and risks of exercises for diabetics (4) Terapeutic estrategis.
During exercise, muscle utilises metabolic fuels at an increased rate to provide the inergy
required for contraction. In healthy individual, muscle glycogen is the predominant fuel
used during very stenuous, short term exercise, whereas blood-borne glucose and free
fatty acids (FFA) derived from adipose tissue triglycerides are used preferentially during
prolonged exercise of low to moderate intensity. Glucose uptake by muscle increases 4 -
to 5 - fold or more during exercises. Despite this, the level of glucose in the plasma is
maintained as a result of enhanced glucose produciton by the liver.
At the onset of exercise and before increased oxygen transport by the circulatory system,
the anaerobic breakdown of glycogen to form lactate provides an immediate source of
adenosine triphosphate (ATP). Exercise that continues more than 30 minutes increases
the dependence on blood borne energy sources. After 60 a 90 minutes of exercise, FFA
are the principal energy source. The utilization of FFA continues to discrease as the
duration of exercises increases. The “ability” to use glucose and to a greater extent FFA
as an energy source is greatly influenced by endurance training. Trained subjects use a
higher proportion of FFA than untramed subjects and are able to spare glycogen stores
while minimizing lactate production: Occasionally singnificant hyperglycemia and
clinically important hypoglycemia occur in normal individuals. Plasma glucose, nowever,
remains within a narrow range when exercising at moderate intensities (30% a 60%) CO2
max.
Changes in glucose homeostasis in the type I diabetic are variable and depend on the
following factors: degree of insulin administration, prior metabolic control, the presence
or absence of autonomic neuropathy, and caloric intake. Balanced energy supply and
insulin availability can have significant effects on the exercising athlete with type I
diabetes. Excessive insulin levels suppress hepatic glucose production, and lowred serum
glucose levels may be met by deficient glucagon secretion, which is common after
several years of disease.
Finally, the type I diabetic does not increase insulin secretion postexercise.
Hyperglycemia after exertion can be profound and prolonged for days owing to insulin
deficiency. In the presence of poor control and ketonuria, further exercise can lead to
impaired glucose uptake and increased lipolysis, ketogenesis, and hepatic glucose
production. The patient may rapidly unless exogenous insulin is given to the patient.
Initial treatment of type II diabetes consists of weight reduction, dietary control, exercise,
and oral hypoglycemic agents. Insulin replacement is seldom necessary but should be
added to the treatment regimen when hyperglycemia remains unchecked by these
methods. Exercise is a major contributor in controlling hyperglycemia through improved
peripheral insulin sensitivity, enhanced insulin binding, and reduced obesity.
Exercise can aid glycemic control and in combination with proper diet help prevent type
II diabetes from occurring in those persons at risk. Exercise does this by improving short-
term insulin sensitivity and reducing insulin resistance, both of which begin to disappear
a few days after exercise is discontinued. Althought the number of insulin receptors
remains constant with exercise, the biding of insulin to adipocytes is increased with no
increase noted in binding to myocytes. In both cell types, however, the number and
activity of glucose transport proteins (particularly Glut-4-isoform) are increased with
exercise. This results in an increase in insulin-stimulated glucose transport into these cells
following exercise, which improves glycemic control.
With the onset of exercise, the type II patient, does not respont with a decrease in serum
glucose concentration as in the nondiabetic. This is due to increased glucose uptake in the
peripheral tissues. As a result, serum glucose is higher, and liver glucose production is
halted to allow for normalization of the hyperglycemia by overall reduction in the
glucose level. In constrast to the type I patient, type II diabetics do not usually suffer
hypoglycemia because endogenous insulin levels can usually be maintained. Those
athletes on oral hypoglycemic agents or insulin, however, may have problems with
glucose homeostasis during exercise. The athlete may need to lower the medication dose
or increase carbohydrate intake (or both) before exercise to prevent hypoglycemia.
Severe hypoglycemia is unusual because individuals are still able to reduce endogenous
insulin production as blood glucose levels decline.
Bibliography